Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira

U.S. Specialty Injectable segment drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hospira

4Q Revenues: $1.1 billion (+4%)

4Q Earnings: $35.8 million (+7%)

FY Revenues: $4.5 billion (+12%)

FY Earnings: $333.2 million (loss of $8.3 million FY13)

Comments: Growth in the quarter was driven by U.S. Specialty Injectable Pharmaceuticals (SIP), up 6% to $606.8 million, and Other Pharma sales, up 24% $130.1 million, offset by the expected decline of Precedex, docetaxel and Medication Management sales, related to the divestiture of the TheraDoc clinical surveillance software business. Global SIP sales in the quarter were $752.8 million, up 3%, and Other Pharma sales were $163.0 million, up 25%. In the quarter, Pfizer entered into a definitive merger agreement to acquire Hospira for approximately $17 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics